Chlamydia Infection Treatment Market Share

Global Chlamydia Infection Treatment Market Overview

Chlamydia Infection Treatment Market Size was valued at USD 2.81 Billion in 2023. The Global Chlamydia Infection Treatment industry is projected to grow from USD 3.01 Billion in 2024 to USD 5.27 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.28% during the forecast period (2024 - 2032).

Chlamydia is a Sexually Transmitted Infection (STI) caused by Chlamydia trachomati. The treatment regimen for chlamydia includes a course of antibiotics. The rise in sexually transmitted disease and increasing prevalence of chlamydia drives the growth of the chlamydia infection treatment market. Moreover, increasing awareness among the population for STDs and rising government initiatives to spread awareness for the STDs is further driving the growth of the market. 

According to the Centers for Disease Control and Prevention (CDC), the chlamydial infection has the highest prevalence in people aged ≤24 years in the US. Moreover, asymptomatic infection is also very common among people. Therefore, annual screening of all sexually active women aged <25 years and older women at increased risk of infection is recommended.

COVID-19 Analysis of Chlamydia Infection Treatment Market:

The rising prevalence of COVID-19 is projected to influence market growth over the forecast period.  As the coronavirus outbreak continues, the majority of pharmaceutical companies experienced a significant loss, thereby hampering the chlamydia infection treatment market. Many companies had restricted or halted their manufacturing and supply operations in the initial phase of the pandemic. However, the current situation of COVID-19 is expected to reach normalcy since the medical professionals and health authorities in the countries are taking the necessary steps to fight against the virus.Social distancing guidelines and resource reallocation in the course of the COVID-19 pandemic have led to significant disruption of sexual health clinics globally.

Moreover, the supply shortage of Active Pharmaceutical Ingredients (APIs) and finished products, especially for antibiotics, has also impacted the chlamydia infection treatment market. To avoid shortages for the necessary pharmaceutical products, theFDA and European Commission proposed and published regulations focusing on-demand optimization and rational supply. These regulation revisions included several regulations to enhance imports in order to maintain integration of the supply chain.

As a result of the COVID-19 crisis and the subsequent global disruptions to supply and demand, world GDP fell sharply during the first half of 2020. According to the World Bank, there will be a 5.2% decrease in global GDP in 2020. Moreover, every region is subjected to considerable growth downgrades; the Middle East & North Africa by 4.2%, Europe & Central Asia by 4.7%, South Asia will contract by 2.7%, and Latin America by 7.2%. However, East Asia & the Pacific region is expected to grow by 0.5%. These downturns are expected to reverse back in due course of time.

Chlamydia Infection Treatment Market Dynamics:

Market Drivers

Rise in sexually transmitted disease and increasing incidence of chlamydia

• Globally, there has been a rise in sexually transmitted diseases. According to CDC, in the US, 2.5 million cases were reported for the three most commonly reported STDs—chlamydia, gonorrhea, and syphilis—in 2019. Moreover, there has been about a 30% increase in these reportable STDs between 2015 and 2019. According to the CDC, In 2019, a total of 1,808,703 cases of Chlamydia trachomatis infection were reported. Likewise, according to the European Centre for Disease Prevention and Control (ECDC), more than 260,000 confirmed cases of STDs were reported from 30 European Economic Area (EEA) countries between 2007 and 2017.Thus, the increasing burden of STDs globally drives the growth of the chlamydia infection treatment market.

Rising government initiatives to promote awareness for the STDs

• The rising economic burden of STDs has led to an increase in government initiatives to spread awareness for the STDs. Increasing government-sponsored programs for spreading awareness and initiatives likefree diagnostic camps to spread awareness for promoting regular health check-ups drives the growth of the chlamydia infection treatment market. For instance, Community Approaches to Reducing Sexually Transmitted Diseases (CARS) is one of the initiatives by the US CDC. The Division of STD Prevention awarded USD 3.6 million for a CARS Phase 3 funding cycleto the organizations including Capacity Builders, Inc., Cicatelli Associates, Inc., San Diego State University Foundation, andWake Forest University Health Sciences. Thus, rising government initiatives to promote awareness for STD drives the growth of the chlamydia infection treatment market.

Increasing use of screening for the disease

• There has been an increase in awareness for screening for disease among the population and a rise in demand for regular health check-ups. Moreover, the increasing number of diagnostic centers and the availability of Direct-to-consumer (DTC) testing kits further support the market’s growth. Recently, there has been an increase in demand for health check-up services that provide DTC testing kits. Several players in the DTC testing market provide sexual health testing products, which include testing for STDs.Thus, the increasing use of screening for the disease is anticipated to boost the growth of the chlamydia infection treatment market.

Market Restraints

Social stigma associated with the STDs

• Despite the need for regular testing for STDs, people often avoid testing for STDs due to social stigma; this can lead to reduced screening, prevention, and care, thereby impeding the growth of the chlamydia infection treatment market.Many times patients also refrain from sharing their details regarding their sex life with the doctors, which further restrains the growth of the chlamydia infection treatment market.

Low rate of screeningfor disease in developing countries

• The developing countries often lack the infrastructure and facilities to support regular testing for STDs. The low presence of diagnostic centers and lower income among the populationoften results in a lower rate of screening for the disease. Moreover, a lack of awareness among the vast majority ofthe population in such countries further restraints the market.

Market Opportunities

Development of new and alternative treatment for Chalymdia

• The current medication for chlamydiagenerally includes treatment with antibiotics. The increasedrisk of the development of antibiotic resistance is a matter of concern for public health.Several pipeline drugs are being researched asthe alternative to antibiotics for chlamydia. For instance, recently, researchers from the University of Waterloodeveloped ananoparticle formulation witha siRNA-based drug to prevent and treat chlamydia.Thus, advances in nanotechnology and pharmaceutical formulations will provide significant opportunities for developing new and alternative treatments for chlamydia, which will further provide significant growth opportunities.

Chlamydia Infection Treatment Market Segment Overview

By Causative Organisms

• Chlamydia trachomatis

Chlamydia trachomatis, is a gram-negative bacteria that cause chlamydia and is the most common sexually transmitted bacterium. These commonly cause genital tract infections and may resemble a gonorrhea infection. They are also associated with blindness and arealso a responsible form of inclusion conjunctivitis. The chlamydia infection treatment market is expected to hold a considerable market share in 2020, owing to the high prevalence of the disease.

• Chlamydophila pneumoniae

Chlamydia pneumoniae, is a gram-negative bacteria that commonly causes pneumoniaand is also responsible for community-acquired pneumonia.The Chlamydia pneumoniaesegment is anticipated to be driven by the increasing outbreaks of community-acquired pneumonia.

By Route of Administration

• Oral

The oral route of administration is one of the most common and frequently used routes for drug administration.A drug given through this route is absorbed into the systemic circulation from the gastrointestinal tract. The oral route of administration is the most preferred route owing to the various advantages such assimple and convenient for the patient, non-invasive, can be self-administered, and generally are safe and cheap.The oral route of administrationsegment accounted for the largest share in the chlamydia infection treatment market in 2020.

• Injectable

Injectable route of administration is among the most common health care procedures globally. Intravenous (IV), subcutaneous (SC), and intramuscular (IM) are the three most frequently used injection routes in medication administration. These offer several advantages, including immediate effect, and can be given to unconscious patients. Injectable route of administration segment accounted for the considerable share in the chlamydia infection treatment market in 2020.

• Others

Others include other routes of administration such as nasal, dermal, and others.

By Distribution Channel

• Hospital Pharmacy

A hospital pharmacy is a dispensary within a hospital that stocks and dispenses medications to inpatients and outpatients. Hospital pharmacy offers easy accessibility of medicines to patients and caters to the demand for a large patient pool. The increase in hospital admissions and a growing number of hospitals globally support the growth of the chlamydia infection treatment market segment.

• Online Pharmacy

Online pharmacy includes internet-based vendors that deliver and distribute medicines to consumers via online platforms. There’s a high demand for online pharmacy owing to the rapid expansion of the internet, growing digital health,and the ease of mail-order trade.

• Retail Pharmacy

Retail pharmacy includes brick-and-mortar shops vendors that distribute and dispense medicines to consumers. Retail pharmaciesare most accessible to the public, and they help in dispensing prescription and over-the-counter drugs.

Chlamydia Infection Treatment Market By Region

• North America:

The North American chlamydia infection treatment market accounted for the largest share in 2020,owing to the well-established healthcare system,the high adoption rateofmedical screening, and presence of a high number of pharmaceutical and biopharmaceutical companies. Moreover, the high prevalence of STDs and rising government initiatives to spread awareness for STDs also drive the growth of the market. Furthermore, the presence of major market players in this region and their contribution through merger &acquisition and product launch is also boosting the market chlamydia infection treatment market growth.

• Europe: 

The European chlamydia infection treatment market is driven by the rising R&D expenditure by biopharmaceutical companies and increasing investment in the R&D sector. The presence of key market players also playsa significant role in contributing to market growth. Moreover, increasing government initiatives to control the spread of STDs further drives the growth of the chlamydia infection treatment market.

• Asia-Pacific:

The Asia-Pacific chlamydia infection treatment market is expected to be the fastest-growing due to rapidly growing and improving healthcare infrastructure, increasing demand for medical screening, and increasing awareness for STDs. In addition, factors such as the growing biopharmaceutical industry, increasing government support, significant investments by key market players, and developing R&D infrastructure also support the growth of this market.

• Rest of the World:

Rising per capita expenditure of the population in the healthcare sector and increasing adoption rate of medical screeningare major factors contributing to the growth of the chlamydia infection treatment market in this region.Moreover, the increasing presence of key pharmaceutical companies in the region further drives the growth of the market.

Competitive Landscape

The chlamydia infection treatment market is profitable, both for existing players as well as new entrants. A substantial level of rivalry is observed among the existing manufacturers in the market. Our analysis revealed that market players have adopted different strategies and innovative research and development techniques to expand their business and secure their position in the global chlamydia infection treatment market. For instance, in August 2019, Statens Serum Institut, completed clinical phase 1 trial for a first-generation vaccine candidate (CTH522), based on the major outer membrane protein of the C trachomatis bacterium. The vaccine will provide a promising preventive therapy for chlamydia infection.

Merck & Co. Inc. has a robust industry experience and is one of the leading companies in the chlamydia infection treatment market. Furthermore, a high customer satisfaction level, exceptional performance in new markets, and a strong product portfolio add to the company’s competitive advantage. The company also has a strong clientele and is well established in the industry. Also, it is continuously involved in seminars, conferences, and trade fairs in several countries to generate awareness about its products.

Many market players are dominating the global chlamydia infection treatment market. The prominent players are involved in strategic agreements, product launches, and joint ventures to sustain their market positions.

List of Key Companies Covered in Chlamydia Infection Treatment Market report:

• Merck & Co. Inc. (US)


• Pfizer Inc (US)


• GlaxoSmithKline Plc(UK)


• AstraZeneca (UK)


• Gilead Sciences Inc. (US)


• Sanofi(France)


• TevaPharmaceuticals (Israel)


• Sun Pharma(India)


• Eli Lilly and Company (US)


• Novartis (Switzerland)

Recent Developments

• In August 2019,Statens Serum Institut, completed clinical phase 1 trial for first-generation vaccine candidate (CTH522), based on the major outer membrane protein of the C trachomatis The vaccine will provide a promising preventive therapy for chlamydia infection


• In March 2019, the Global Antibiotic Research and Development Partnership (GARDP) announced a public-private partnership with Evotec AG for the development of first-in-class antibiotics for the treatment of drug-resistant bacterial infections


• In 2018, the National Institutes of Health (NIH) made a significant new investment in vaccine research for gonorrhea, chlamydia, and syphilis. Furthermore, an investment of USD 9 million was anticipated to be made in 2019 to fund three to five grants for the research

Report Overview

The study covers the existing short-term and long-term chlamydia infection treatment market effect, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the rest of the world. The report analyzes market drivers, restraints, opportunities, challenges, Porter’s Five Forces, Value Chain, and impact of COVID-19 on the market. 

Scope of the Report 

The scope of the global chlamydia infection treatment market study includes a market size analysis and a detailed analysis of the manufacturer’s products and strategies. The chlamydia infection treatment market has been segmented based on causative organisms, route of administration, distribution channel, and region.

Chlamydia Infection Treatment Market Segmentation

Global Chlamydia Infection Treatment Market, by Causative Organisms

• Chlamydia trachomatis


• Chlamydophila pneumoniae

Global Chlamydia Infection Treatment Market, by Route of Administration

• Oral


• Injectable


• Others

Global Chlamydia Infection Treatment Market, by Distribution Channel

• Hospital Pharmacy


• Online Pharmacy


• Retail Pharmacy


• Others

Global Chlamydia Infection Treatment Market, by Region

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East&Africa
  
  
  • Latin America